Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01209078 · ClinicalTrials.gov registry record · Phase 2
GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT01209078 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 84 participants.
The verdict
NCT01209078, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
This study will determine the safety, tolerability and efficacy of GSK1322322 verses Linezolid in subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Interventions
- DRUG Linezolid
- DRUG GSK1322322
- DRUG GSK1322322 placebo
- DRUG Linezolid placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2010-08-17 |
| Est. Completion | 2011-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01209078
The ClinicalTrials.gov registry entry for NCT01209078 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Linezolid is the first listed.
NCT01209078 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01209078 about?
NCT01209078 is a clinical study titled "GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection". This study will determine the safety, tolerability and efficacy of GSK1322322 verses Linezolid in subjects with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
What is the current status of trial NCT01209078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2010-08-17. Estimated completion is 2011-01-18.
What interventions are being tested in trial NCT01209078?
The interventions under investigation include: Linezolid (DRUG), GSK1322322 (DRUG), GSK1322322 placebo (DRUG), Linezolid placebo (DRUG).
Who is sponsoring clinical trial NCT01209078?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.